Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry.

ABSTRACT:

Introduction

Lung cancer remains the leading cause of cancer-related death with poor survival due to the late stage at which lung cancer is typically diagnosed. Given the clinical burden from lung cancer and the relatively favorable survival associated with early-stage lung cancer, biomarkers for early detection of lung cancer are of important potential clinical benefit.

Methods

We performed a global lung cancer serum biomarker discovery study using liquid chromatography-tandem mass spectrometry in a set of pooled non-small cell lung cancer case sera and matched controls. Immunoaffinity subtraction was used to deplete the top most abundant serum proteins; the remaining serum proteins were subjected to trypsin digestion and analyzed in triplicate by liquid chromatography-tand

SUBMITTER: Zeng X 

PROVIDER: S-EPMC3104087 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature